1. Home
  2. LFUS vs BLCO Comparison

LFUS vs BLCO Comparison

Compare LFUS & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Littelfuse Inc.

LFUS

Littelfuse Inc.

HOLD

Current Price

$386.81

Market Cap

6.9B

Sector

Energy

ML Signal

HOLD

Logo Bausch + Lomb Corporation

BLCO

Bausch + Lomb Corporation

HOLD

Current Price

$16.84

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LFUS
BLCO
Founded
1927
1853
Country
United States
Canada
Employees
N/A
N/A
Industry
Electrical Products
Ophthalmic Goods
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.9B
6.0B
IPO Year
1996
2022

Fundamental Metrics

Financial Performance
Metric
LFUS
BLCO
Price
$386.81
$16.84
Analyst Decision
Strong Buy
Buy
Analyst Count
3
12
Target Price
$366.67
$18.45
AVG Volume (30 Days)
202.8K
387.4K
Earning Date
05-06-2026
04-29-2026
Dividend Yield
0.77%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$757,853,000.00
$5,101,000,000.00
Revenue This Year
$14.61
$8.63
Revenue Next Year
$7.02
$5.58
P/E Ratio
N/A
N/A
Revenue Growth
N/A
6.47
52 Week Low
$150.07
$10.45
52 Week High
$391.68
$18.92

Technical Indicators

Market Signals
Indicator
LFUS
BLCO
Relative Strength Index (RSI) 66.77 54.64
Support Level $241.48 $16.35
Resistance Level N/A $17.66
Average True Range (ATR) 12.53 0.45
MACD 5.16 0.13
Stochastic Oscillator 92.44 91.35

Price Performance

Historical Comparison
LFUS
BLCO

About LFUS Littelfuse Inc.

Littelfuse is a primary provider of circuit protection products (such as fuses and relays) for the transportation, industrial, telecommunications, and consumer electronics end markets. The company is also increasing its power semiconductor business, where it predominantly serves industrial end markets, and is breaking into electric vehicle charging infrastructure. Littelfuse has 17,000 global employees.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: